Market Overview

XenoPort May Be Beneficiary of Biogen Patent Filings

Share:
Related BIIB
Baird Still Isn't Buying Biogen
15 Biggest Mid-Day Gainers For Thursday
The Vetr community has upgraded $BIIB to 3-Stars. (Vetr)
Related XNPT
Benzinga's M&A Chatter for Monday May 23, 2016
Mid-Afternoon Market Update: KLX Drops On Q1 Results; Resource America Shares Spike Higher

Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT).

Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.

BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.

Latest Ratings for BIIB

DateFirmActionFromTo
Jul 2016Morgan StanleyMaintainsOverweight
Jun 2016BernsteinInitiates Coverage onOutperform
Jun 2016CitigroupMaintainsBuy

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (BIIB + XNPT)

View Comments and Join the Discussion!